Conference: ACoP 2025
Date: October 18 - 21, 2025
Location: Aurora, CO
Booth: 17 & 18
Platinum Sponsor
Product Launches at ACoP
We’re unveiling two major innovations transforming the future of modeling and simulation in drug development. Join us at ACoP to get a first look at the latest solutions from Certara designed to empower your teams with speed, scalability, and scientific precision.
Introducing Certara IQ
The Future of QSP is Here
Certara IQ is an AI-enabled SaaS platform built to scale and standardize Quantitative Systems Pharmacology (QSP) across R&D portfolios. With a user-friendly model-building interface, access to pre-validated QSP models, and regulatory-ready reporting templates, IQ accelerates model development and promotes seamless collaboration across teams.
Key features include:
- Intuitive, drag-and-drop model construction
- High-performance cloud-based simulation
- Standardized workflows and reusable frameworks
- Secure, scalable infrastructure for team collaboration
Certara IQ eliminates manual, time-consuming tasks and enables scientists to focus on high-value insights—making QSP faster, more accessible, and more impactful across the drug development lifecycle.
Phoenix® Cloud
Gold-Standard PK/PD. Now in the Cloud.
Phoenix® Cloud brings the industry’s leading PK/PD modeling software into a modern, environment—enabling flexible, frictionless workflows that evolve with your needs.
New capabilities include:
- Integrated cloud-native data management
- GenAI-powered reporting
- Publication-quality graphing tools
- Scalable infrastructure for collaboration and rapid analysis
From data ingestion to final report, Phoenix Cloud enhances productivity and ensures consistency—helping PK/PD teams meet growing development demands with greater efficiency.
Where to hear Certara insights and expertise
Workshops
Presenters: Joshua F. Apgar, Andrew Matteson, Sasha Sherman, David Flowers
With hundreds of FDA and EMA submissions supported by QSP models, QSP has finally come of age. The now proven high return of investment from QSP has led to every major pharma company, and a significant number of biotechs investing in QSP groups or partnering with QSP vendors. However, the vast majority of preclinical and clinical programs are still not supported by QSP. At this point we see this not as a limitation of the value of QSP but as a challenge for implementing QSP at scale. This workshop will unveil Certara IQ, an innovative QSP environment that enables the scaling of QSP from only supporting a small minority of projects, to supporting the entire pipeline. We will focus on four key decision points in the drug development pipeline:
- New Target Feasibility
- Determining Best in Class Properties
- First In Human Dose Projection
- Recommended Phase 2 Dose
For each we will demonstrate how to use Certara IQ to efficiently answer these questions with worked practical examples.
Preconference Sessions
Speaker: Hannah M. Jones, PhD
Location: Willow Lake 3-5
Speaker: Matthew Zierhut
Location: Willow Lake 3-5
Speaker: Paul M. Diderichsen
Location: Willow Lake 3-5
Conference Sessions
Special Populations
Speaker: Sibylle Neuhoff
Location: Colorado B-D
Chair: Fei Hua (panel)
Speaker: Doug Chung (panel)
Speaker/Panelist: Fei Hua (panel)
Location: Willow Lake 3-5
Chair: Matt Zierhut
Location: Red Rock 8&9
Speaker/Panelist: Kimiko McGirr
Speaker/Panelist: Kimiko McGirr
Location: Colorado B-D
Chair: Hunter Stephens
Location: Red Rock 8&9
Unravelling the pharmacokinetics of oligonucleotides by using a PBPK model
Speaker: Felix Stader
Location: Willow Lake 3-5
Post-conference workshop
Presenters: Matthew L. Zierhut, PhD, MBA and Paul M. Diderichsen, PhD
Location: Red Rock 2
Attendees of this one-day workshop will learn about model-based meta-analysis (MBMA) – starting with the basic principles of meta-analysis and moving toward detailed applications of complex MBMA methodologies. Concepts will be explained using case studies, accompanied by detailed hands-on R scripts and real datasets. We will also explore datasets and perform directed analyses using Certara’s CODEX software platform.
- Some critical topics include:
- MBMA of binary and continuous data
- Dose-response MBMA
- Longitudinal MBMA
- Relative effect vs absolute outcome modeling
- Unstructured (nonparametric) placebo methodology
- Random effects and weighting of data
- Data transformations
- MBMA covariate exploration
- Joint MBMA of multiple endpoints
Posters
Authors: Bill Poland, Irene Bae
Sponsor: Merck & Co., Inc.
Authors: Shuang Xu, Bill Poland
Sponsor: Kartos
Authors: Leandro Pippa, Hunter Stephens, Stephen Duffull, Mirjam Trame
Sponsor: Certara
Authors: Hunter Stephens, Mirjam Trame; Diane-Charlotte Imbs, Amandine Manon
Sponsor: Certara
Author: Hunter Stephens
Sponsors: Certara, Novartis, Genentech
Authors: Shuang Xu, Bill Poland
Sponsor: Gilead
Authors: Anna Gaffney, Mirjam Trame
Sponsor: Certara
Authors: Carol Conchon Costa, Keith Nieforth, Mark Sale
Sponsor: Certara
Authors: Ahmed Abulfathi, Sergio Iadevaia, Stephen Duffull
Sponsor: Certara
Authors: Ahmed Abulfathi, Mirjam Trame
Sponsors: Certara, GMRI
Authors: Li Qin, Shuai Fu, Ahmed Abulfathi, Matt Zierhut
Sponsors: Certara, GSK
Authors: Todd Dumas, Shahram Mehr
Sponsors: Certara, ADMA Biologics
Authors: Bill Poland, Shuang Xu
Sponsor: Gilead Sciences
Authors: Swati Debroy, Shahram E. Mehr, Craig Comisar
Sponsor: Tourmaline Bio
Author: Dennis Reddyhoff
Discover how Certara’s tech-enabled services and software can propel your program forward at every phase of drug development.
Get started! Book your consultation with one of our experts now and take the first step towards optimizing your development programs.
